SOL Earnings

SOL reported its FY2024Q4 earnings on 2025-03-13, showcasing a revenue of 34.55M against an estimate of 40.13M, resulting in a -13.9% surprise. The EPS was -0.23, surpassing the expected 0.08 by -387.5%. The stock experienced a -19.05% price change on the earnings day and a 16.33% change over the next five days, reflecting market reactions to the results.

Following SOL's FY2024Q4 earnings announcement on 2025-03-13, the stock price moved by -19.05% on the day of the release. Over the subsequent five days, it saw a 16.33% change. Historically, SOL's stock price tends to shift by an average of 0.54% in the 10 days leading up to earnings and -0.65% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SOL's annual revenue to reach 29.20M, while the EPS is projected at 0.08. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SOL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SOL's stock price typically moves by 0.54% in the 10 days before its earnings and -0.65% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.08 and revenue of 29.20M.

The earnings call reveals several concerning factors: a 23% YoY revenue decline due to project delays, operating and net losses, and increased debt-to-asset ratio. While there are positive aspects like improved gross margins and strong cash flow, the uncertainty in government approvals and lack of clear guidance on free cash flow are troubling. The Q&A section highlighted potential risks, especially in the US market. Overall, the negative elements outweigh the positives, leading to a likely stock price decline in the range of -2% to -8%.